Spots Global Cancer Trial Database for Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Official Title: Evaluating the Efficacy and Safety of Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Study ID: NCT06350825
Study Description
Brief Summary: To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)
Detailed Description: To investigate the multimodality approaches for mHSPC
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Contact Details
Name: Lixin Hua, M.D.
Affiliation: The First Affiliated Hospital with Nanjing Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
